INVALID TRIAL
CHIA and your personal trial have no criteria in common

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤═════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria   │   Score │
╞════════════════════════════════════════════════════╪═════════════════╪═════════╡
│ Otherwise healthy, 12-49 years old, identical (MZ) │ NA              │       0 │
│ or fraternal (DZ) twins                            │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Willing to complete the informed consent process   │ NA              │       0 │
│ (including assent for minors 12-17 years of age,   │                 │         │
│ inclusive)                                         │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Must have minimum age of 12 Years                  │ NA              │       0 │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Must have maximum age of 49 Years                  │ NA              │       0 │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ and vital signs                                    │ NA              │       0 │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Exclusion Criteria                                 │ NA              │       0 │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Prior off-study vaccination with the current       │ NA              │       0 │
│ year's seasonal influenza vaccine                  │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Life-threatening reactions to previous influenza   │ NA              │       0 │
│ vaccinations                                       │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ History of immunodeficiency (including HIV         │ NA              │       0 │
│ infection)                                         │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Known or suspected impairment of immunologic       │ NA              │       0 │
│ function, including, but not limited to,           │                 │         │
│ clinically significant liver disease, diabetes     │                 │         │
│ mellitus treated with insulin, moderate to severe  │                 │         │
│ renal disease, or any other chronic disorder       │                 │         │
│ which, in the opinion of the investigator, might   │                 │         │
│ jeopardize volunteer safety or compliance with the │                 │         │
│ protocol                                           │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Blood pressure \>150 systolic or \>95 diastolic at │ NA              │       0 │
│ first study visit and the day of vaccination       │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Hospitalization in the past year for congestive    │ NA              │       0 │
│ heart failure or emphysema                         │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Chronic Hepatitis B or C                           │ NA              │       0 │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Recent or current use of immunosuppressive         │ NA              │       0 │
│ medication, including systemic glucocorticoids     │                 │         │
│ (corticosteroid nasal sprays and topical steroids  │                 │         │
│ are permissible in all groups; inhaled steroid use │                 │         │
│ is not permissible)                                │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Malignancy, other than squamous cell or basal cell │ NA              │       0 │
│ skin cancer (includes solid tumors such as breast  │                 │         │
│ cancer or prostate cancer with recurrence in the   │                 │         │
│ past year, and any hematologic cancer such as      │                 │         │
│ leukemia)                                          │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ History of blood dyscrasias, renal disease, or     │ NA              │       0 │
│ hemoglobinopathies requiring regular medical       │                 │         │
│ follow up or hospitalization during the preceding  │                 │         │
│ year                                               │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ For children or adolescents through 17 years of    │ NA              │       0 │
│ age, receiving aspirin therapy or aspirin-         │                 │         │
│ containing products (If yes, not eligible for      │                 │         │
│ Group C)                                           │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Receipt of blood or blood products within the past │ NA              │       0 │
│ 6 months or planned used during the study          │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Medical or psychiatric condition or occupational   │ NA              │       0 │
│ responsibilities that preclude participant         │                 │         │
│ compliance with the protocol                       │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Receipt of inactivated vaccine 14 days prior to    │ NA              │       0 │
│ study enrollment, or planned vaccinations prior to │                 │         │
│ completion of last study visit (\~ 28 days after   │                 │         │
│ study vaccination)                                 │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Receipt of live, attenuated vaccine within 60 days │ NA              │       0 │
│ prior to enrollment of planned vaccination prior   │                 │         │
│ to completion of last study visit (\~ 28 days      │                 │         │
│ after study vaccination)                           │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Has taken an influenza antiviral medication within │ NA              │       0 │
│ 48 hours prior to study vaccination (If yes, not   │                 │         │
│ eligible for Group C)                              │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ History of Guillain-Barré syndrome                 │ NA              │       0 │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Pregnant woman                                     │ NA              │       0 │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Lactating woman (If yes, not eligible for Group C) │ NA              │       0 │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Use of investigational agents within 30 days prior │ NA              │       0 │
│ to enrollment or planned use during the study      │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Donation of the equivalent of a unit of blood      │ NA              │       0 │
│ within 6 weeks prior to enrollment or planned      │                 │         │
│ donation prior to completion of the last visit     │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ In close contact with anyone who has a severely    │ NA              │       1 │
│ weakened immune system and requires a protective   │                 │         │
│ environment (If yes, may be ineligible for Group   │                 │         │
│ C; exposure to such persons should be avoided for  │                 │         │
│ 7 days after receipt of LAIV)                      │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Autoimmune disease (including rheumatoid arthritis │ NA              │       1 │
│ treated with immunosuppressive medication such as  │                 │         │
│ Plaquenil, methotrexate, prednisone, Enbrel)       │                 │         │
│ which, in the opinion of the investigator, might   │                 │         │
│ jeopardize volunteer safety or compliance with the │                 │         │
│ protocol                                           │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Use of any anti-coagulation medication such as     │ NA              │       1 │
│ Coumadin or Lovenox, or anti-platelet agents such  │                 │         │
│ as aspirin (except up to 325 mg. per day), Plavix, │                 │         │
│ or Aggrenox must be reviewed by investigator to    │                 │         │
│ determine if this would affect the volunteer's     │                 │         │
│ safety                                             │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Any condition which, in the opinion of the         │ NA              │       1 │
│ investigator, might interfere with volunteer       │                 │         │
│ safety, study objectives or the ability of the     │                 │         │
│ participant to understand or comply with the study │                 │         │
│ protocol                                           │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Availability for follow-up for the planned         │ NA              │       2 │
│ duration of the study at least 28 days after       │                 │         │
│ immunization                                       │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Allergy to egg or egg products, or to vaccine      │ NA              │       2 │
│ components, (including gentamicin, gelatin,        │                 │         │
│ arginine or MSG in LAIV)                           │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Active systemic or serious concurrent illness,     │ NA              │       2 │
│ including febrile illness on the day of            │                 │         │
│ vaccination                                        │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Need for allergy immunization (that cannot be      │ NA              │       2 │
│ postponed) during the study period                 │                 │         │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Acceptable medical history by review of inclusion/ │ NA              │       4 │
├────────────────────────────────────────────────────┼─────────────────┼─────────┤
│ Asthma (If yes, not eligible for Group C)          │ NA              │       5 │
╘════════════════════════════════════════════════════╧═════════════════╧═════════╛

Only CHIA has the following criteria:
╒═══════════════════════════════════════════╤═════════════════╤═════════╕
│ Personal Criteria                         │ CHIA Criteria   │   Score │
╞═══════════════════════════════════════════╪═════════════════╪═════════╡
│ Asthma (If yes, not eligible for Group C) │ NA              │       5 │
├───────────────────────────────────────────┼─────────────────┼─────────┤
│ Asthma (If yes, not eligible for Group C) │ NA              │       5 │
╘═══════════════════════════════════════════╧═════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 0
Average Levenshtein Ratio of individual lines: 0.7948717948717948
OverAll Ratio: 0.3974358974358974
